Knowledge Library
CDK4/6 Inhibitor Resistant Breast Cancer Models
Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including: In vitro induced Palbociclib resistant MCF-7 cell line In vivo induced Palbociclib resistant MCF-7 model In vivo induced Abemaciclib resistant MCF-7 model In vivo induced Ribociclib resistant MCF-7 model View additional drug-resistant models in our platform
Ligand Finding and Chemistry Workflows for Targeted Protein Degradation
This webinar will focus on aspects related to PROTAC discovery and chemistry workflows, such as ligand finding strategies, synthesis optimization, and linker design. Successful development of bifunctional molecules requires a deep understanding of multiple processes, including biophysical events which dictate induced proximity and how technologies such as DNA-encoded libraries (DEL) can be leveraged to identify …Read More >
Biological Characterization and Development Workflows for Targeted Protein Degradation
This webinar will focus on PROTAC biology workflows, such as in vitro screening assays, in vivo testing, and optimization of DMPK properties. Topics will include the best use of biochemical assays to measure binary/ternary complex formation, cell-based assays to assess target engagement and degradation, strategies for enhancing drug delivery and formulation, and PK/PD evaluation of …Read More >
Discovery Newsletter November 2022
How Does It Work? | Antibody Drug Conjugates
In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >
How Does It Work? | Peptibodies
#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >
WuXi AppTec Oligonucleotide Biology Platform
We offer a wide range of oligonucleotide services, including: Sequence design Knockdown effect in cell lines and primary cells Splicing analysis Functional assays and assessment of off-target effects Transgenic, HDI and AAV mouse models GalNAc-ASGPR delivery system and customized assays for other delivery systems Stability and protein-protein binding assays Delivery/RISC PK in mouse, rat, and …Read More >
Pain Discovery Assays & In Vivo Models
WuXi AppTec offers a comprehensive platform to evaluate lead candidates targeting various types of pain, including inflammatory, neuropathic, and fibromyalgia-like pain and osteoarthritis. Our expertise and experience allow us to offer an extensive portfolio of services supporting drug discovery and development, from target discovery to translational research and clinical biomarker testing and beyond. Full-scale molecular …Read More >
OncoWuXi Newsletter: June 2022
WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform